[go: up one dir, main page]

GB201201744D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
GB201201744D0
GB201201744D0 GBGB1201744.8A GB201201744A GB201201744D0 GB 201201744 D0 GB201201744 D0 GB 201201744D0 GB 201201744 A GB201201744 A GB 201201744A GB 201201744 D0 GB201201744 D0 GB 201201744D0
Authority
GB
United Kingdom
Prior art keywords
formula
hydrogen
heteroaryl
3alkoxy
3alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB1201744.8A
Other versions
GB2498976A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prosidion Ltd
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Priority to GB1201744.8A priority Critical patent/GB2498976A/en
Publication of GB201201744D0 publication Critical patent/GB201201744D0/en
Publication of GB2498976A publication Critical patent/GB2498976A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A compound of formula (Ia), (Ib) or (Ic) or pharmaceutically acceptable salts thereof wherein in formula (Ia) A is a phenyl or six-membered heteroaryl having 1-3 N atoms wherein the phenyl or heteroaryl may be optionally substituted; B is selected from H, D, F, hydroxyl, propyn-1-yl, C1-3alkyl, hydroxyC1-3alkoxy, C1-3alkoxy, C1-3alkyl-O-C1-3alkyl, CONR1R2, C1-3alkylCONR1R2, C3-6cycloalkyl, a 4-6 membered heterocyclyl or a 5-6 membered heteroaryl; R1 and R2 are each independently a substituent or NR1R2 together form a 4-7 membered heterocyclic ring; X is O, CH2, N or S; Y is a linker group as herein described; R9 and R10 are independently hydrogen, halo, optionally substituted C1-2alkyl, C1-3alkoxy or hydroxyl or R9 and R10 together form an azabicyclo[3.3.1]nonane, a 3-oxa-7-azabicyclo[3.3.1]nonane or an azabicyclo[3.2.1]octane; R11 is hydrogen, halo, optionally substituted C1-2alkyl or C1-3alkoxy; p and q are each 0, 1 or 2 provided that 0 ¤p+q ¤2 and Z is -C(O)OR4, -C(O)R4, -S(O)2R4, -S(O)2N(C1-3alkyl)R4, phenyl, benzyl, heteroaryl or -CH2-heteroaryl any of which may be optionally substituted and R4 is a substitutent; in formula (Ib) V is a bond, CMe2, a spiroC3-6cycloalkyl or a spiro 4-6 membered heterocycle; W is CH2 or VW together form a C3-6cycloalkyl or a 5-6 membered heterocyclyl and moieties A,B,X,Y,Z,R9,R10,R11,p and q are as defined for formula (Ia); In formula (Ic) E is O, NR8 or S; R3 is hydrogen, fluorine, or propyn-1-yl; R8 is hydrogen, methyl, ethyl, n-propyl or i-propyl; R5, R6 and R7 are independently selected from hydrogen or halo and moieties A,B,X,Y,Z,R9,R10,R11,p and q are as defined for formula (Ia). Compounds of formula (Ia), (Ib) and (Ic) are useful as agonists of GPR119 and GPR40 receptors in the treatment of type II diabetes.
GB1201744.8A 2012-02-01 2012-02-01 GPR119 agonists useful in the treatment of type II diabetes Withdrawn GB2498976A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB1201744.8A GB2498976A (en) 2012-02-01 2012-02-01 GPR119 agonists useful in the treatment of type II diabetes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1201744.8A GB2498976A (en) 2012-02-01 2012-02-01 GPR119 agonists useful in the treatment of type II diabetes

Publications (2)

Publication Number Publication Date
GB201201744D0 true GB201201744D0 (en) 2012-03-14
GB2498976A GB2498976A (en) 2013-08-07

Family

ID=45876471

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1201744.8A Withdrawn GB2498976A (en) 2012-02-01 2012-02-01 GPR119 agonists useful in the treatment of type II diabetes

Country Status (1)

Country Link
GB (1) GB2498976A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114945560A (en) * 2019-10-07 2022-08-26 卡尔优普公司 GPR119 agonists

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2925741B1 (en) 2012-11-16 2016-10-26 Bristol-Myers Squibb Company Pyrrolidine gpr40 modulators
EP2958562B1 (en) 2013-02-22 2025-09-10 Merck Sharp & Dohme LLC Antidiabetic bicyclic compounds
KR101984281B1 (en) * 2013-08-08 2019-05-31 동아에스티 주식회사 Novel compound having activity to gpr119, process of preparing thereof and pharmaceutical compositon comprising the same
WO2015028960A1 (en) * 2013-08-28 2015-03-05 Piramal Enterprises Limited Substituted heterocyclic derivatives as gpr agonists and uses thereof
WO2015073342A1 (en) 2013-11-15 2015-05-21 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2015119899A1 (en) 2014-02-06 2015-08-13 Merck Sharp & Dohme Corp. Antidiabetic compounds
JP6483156B2 (en) * 2014-05-07 2019-03-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Pyrrolidine GPR40 modulators for the treatment of diseases such as diabetes
WO2015176267A1 (en) 2014-05-22 2015-11-26 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2016022742A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US10100042B2 (en) 2014-08-08 2018-10-16 Merck Sharp & Dohme Corp. [5,6]—fused bicyclic antidiabetic compounds
US10662171B2 (en) 2014-08-08 2020-05-26 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2016019587A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [7, 6]-fused bicyclic antidiabetic compounds
WO2017172505A1 (en) 2016-03-29 2017-10-05 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
AU2017355603A1 (en) 2016-11-04 2019-06-20 Auckland Uniservices Limited Tricyclic heterocyclic derivatives and uses thereof
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
WO2019099315A1 (en) 2017-11-16 2019-05-23 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
BR112020015712A2 (en) 2018-02-05 2020-12-08 Alkermes, Inc. PAIN TREATMENT COMPOUNDS
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN115667277A (en) 2020-02-28 2023-01-31 卡尔优普公司 GPR40 agonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007016508A (en) * 2005-06-30 2008-03-04 Prosidion Ltd Gpcr agonists.
GB0812648D0 (en) * 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0812649D0 (en) * 2008-07-10 2008-08-20 Prosidion Ltd Compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114945560A (en) * 2019-10-07 2022-08-26 卡尔优普公司 GPR119 agonists

Also Published As

Publication number Publication date
GB2498976A (en) 2013-08-07

Similar Documents

Publication Publication Date Title
GB201201744D0 (en) Novel compounds
EP4248988A3 (en) Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell
CR9267A (en) QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF LATENT TUBERCULOSIS
NZ588994A (en) Phenyl and benzodioxinyl substituted indazoles derivatives
MX2013011854A (en) Tri- and tetracyclic pyrazolo[3,4-b]pyridine compounds as antineoplastic agent.
NZ629025A (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
CO6331437A2 (en) PIRROLO COMPOUNDS [2,3-D] PYRIMIDINE
MX2013003019A (en) Azabenzothiazole compounds, compositions and methods of use.
MD20140037A2 (en) (4-Phenylimidazol-2-yl)ethylamine derivatives useful as sodium channel modulators
MD20140023A2 (en) Pyrrolopyrimidine and purine derivatives
EA201001013A1 (en) BIS (SULFONILAMINO) DERIVATIVES FOR USE IN THERAPY
UA84878C2 (en) 2-pyridone derivatives as netrophil elastase inhibitors and their preparation
HK1203497A1 (en) Non-systemic tgr5 agonists
MX2014001595A (en) Indazole compounds, compositions and methods of use.
MX2009013078A (en) Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators - 842.
JP2013531029A5 (en)
PH12016500911A1 (en) 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders
WO2007022934A3 (en) Azabicyclo (3, 1, 0) hexan derivatives useful as modulators of dopamine d3 receptors
NO20083708L (en) 4-Phenyl-thiazole-5-carboxylic acid and 4-phenyl-thiazole-5-carboxylmides as PLK1 inhibitors
MY170822A (en) Ethynyl derivatives as mglur5 allosteric modulators
MX2010006787A (en) Halogenated analogues of anti-fibrotic agents.
RU2013136895A (en) NEW BICYCLE COMPOUND OR ITS SALT
MX2016003422A (en) Imidazo[1,2-a]pyridin-7-amines as imaging tools.
PE20142421A1 (en) SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND THEIR USE
MX2014002949A (en) Imidazopyridine compounds, compositions and methods of use.

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)